Torii Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 4/6
Torii Pharmaceutical's earnings have been declining at an average annual rate of -31.2%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been growing at an average rate of 6.4% per year. Torii Pharmaceutical's return on equity is 4.4%, and it has net margins of 9%.
Belangrijke informatie
-31.2%
Groei van de winst
-31.2%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 3.4% |
| Inkomstengroei | 6.4% |
| Rendement op eigen vermogen | 4.4% |
| Nettomarge | 9.0% |
| Volgende winstupdate | 07 Feb 2025 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Torii Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 58,839 | 5,276 | 14,545 | 2,875 |
| 30 Jun 24 | 57,248 | 5,254 | 14,112 | 2,440 |
| 31 Mar 24 | 56,278 | 5,285 | 14,159 | 1,965 |
| 31 Dec 23 | 54,638 | 4,119 | 14,014 | 3,490 |
| 30 Sep 23 | 52,713 | 3,456 | 16,191 | 3,383 |
| 30 Jun 23 | 51,493 | 3,185 | 16,162 | 3,491 |
| 31 Mar 23 | 49,747 | 2,774 | 16,028 | 3,542 |
| 31 Dec 22 | 48,896 | 3,944 | 15,944 | 1,661 |
| 30 Sep 22 | 48,865 | 3,992 | 16,775 | 1,410 |
| 30 Jun 22 | 48,534 | 3,975 | 17,435 | 1,084 |
| 31 Mar 22 | 48,048 | 3,820 | 18,104 | 900 |
| 31 Dec 21 | 46,987 | 3,374 | 18,591 | 832 |
| 30 Sep 21 | 44,965 | 3,225 | 18,134 | 650 |
| 30 Jun 21 | 43,398 | 2,939 | 17,747 | 646 |
| 31 Mar 21 | 42,028 | 3,069 | 16,659 | 647 |
| 31 Dec 20 | 41,700 | 3,495 | 16,165 | 596 |
| 30 Sep 20 | 41,850 | 3,409 | 19,252 | -2,131 |
| 30 Jun 20 | 42,171 | 2,973 | 19,450 | -1,553 |
| 31 Mar 20 | 43,408 | -293 | 20,185 | -929 |
| 31 Dec 19 | 42,998 | 27,367 | 20,864 | 0 |
| 30 Sep 19 | 48,328 | 25,382 | 18,640 | 3,625 |
| 30 Jun 19 | 52,684 | 25,810 | 19,491 | 3,918 |
| 31 Mar 19 | 57,782 | 29,117 | 20,568 | 4,108 |
| 31 Dec 18 | 62,551 | 1,164 | 25,755 | 0 |
| 30 Sep 18 | 63,952 | 4,195 | 21,428 | 4,193 |
| 30 Jun 18 | 64,596 | 4,505 | 21,353 | 4,440 |
| 31 Mar 18 | 64,457 | 4,899 | 21,594 | 4,472 |
| 31 Dec 17 | 64,135 | 4,718 | 21,524 | 4,608 |
| 30 Sep 17 | 62,164 | 3,855 | 21,212 | 4,593 |
| 30 Jun 17 | 61,283 | 3,117 | 21,145 | 4,838 |
| 31 Mar 17 | 60,074 | 2,424 | 21,108 | 4,764 |
| 31 Dec 16 | 60,206 | 2,839 | 21,025 | 4,654 |
| 30 Sep 16 | 61,305 | 2,951 | 21,200 | 5,147 |
| 30 Jun 16 | 61,957 | 3,378 | 21,155 | 4,925 |
| 31 Mar 16 | 62,820 | 3,798 | 21,017 | 5,160 |
| 31 Dec 15 | 62,378 | 3,527 | 21,015 | 5,237 |
| 31 Dec 14 | 58,089 | 3,393 | 20,214 | 4,878 |
| 30 Sep 14 | 57,107 | 3,031 | 19,889 | 5,664 |
| 30 Jun 14 | 56,517 | 2,972 | 19,885 | 6,148 |
| 31 Mar 14 | 58,109 | 3,352 | 19,871 | 6,662 |
| 31 Dec 13 | 55,291 | 2,335 | 19,446 | 7,170 |
Kwaliteitswinsten: 4551 has high quality earnings.
Groeiende winstmarge: 4551's current net profit margins (9%) are higher than last year (6.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 4551's earnings have declined by 31.2% per year over the past 5 years.
Versnelling van de groei: 4551's earnings growth over the past year (52.7%) exceeds its 5-year average (-31.2% per year).
Winst versus industrie: 4551 earnings growth over the past year (52.7%) exceeded the Pharmaceuticals industry 38.7%.
Rendement op eigen vermogen
Hoge ROE: 4551's Return on Equity (4.4%) is considered low.